explore -WSS

explore

author：knowledge 2025-09-30 01:02:49 - browse：3

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： FDA sets aggressive timeline for overhauling inspection procedures

WSS

Harvard's David Sinclair gets blowback over aging

Lack of health data on LGBTQ+ people has serious consequences

Ancient Greek ideas underpin modern concepts of pregnancy

The inclusion problem at the heart of rehabilitation research

Head of FDA's diagnostics center, who led through Covid, retires

CVS is on a mission to consolidate health care. Will it work?

hotspot

explore

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Pregnant women don't need prenatal multivitamins, study concludes

Medical leaders decry Supreme Court decision on affirmative action

Immune cells and nerve overgrowth may explain recurring UTI pain

Medicare details structure of new drug price negotiation program

Medicare drug price negotiation continues, as pharma counteroffers

New air purifier tech could be key to improving indoor air quality

Medicare drug price negotiation continues, as pharma counteroffers

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

High breast density mammograms need follow

hotspot

Longer MASH drug regimen improved liver, Akero study finds

Maisha Meds is a PBM, but don't call it that

Microsoft's Peter Lee: Generative AI could help doctors be more human

Maisha Meds is a PBM, but don't call it that

Stem cell biologist probes earliest stages of human development

Pregnant women don't need prenatal multivitamins, study concludes

focus

entertainment

hotspot

Wikipedia